Technical Analysis for GOVX - GeoVax Labs, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Resistance | Bearish | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Doji - Bearish? | Reversal | 0.00% | |
Earnings Movers | Other | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
20 DMA Support | Bullish | 1.18% | |
Pocket Pivot | Bullish Swing Setup | 1.18% | |
Earnings Movers | Other | 1.18% | |
Outside Day | Range Expansion | 1.18% |
Alert | Time |
---|---|
Possible Pocket Pivot | about 10 hours ago |
Rose Above Previous Day's High | about 14 hours ago |
Rose Above Upper Bollinger Band | about 14 hours ago |
50 DMA Resistance | about 14 hours ago |
2x Volume Pace | about 14 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/14/2024
GeoVax Labs, Inc. Description
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; CaroGen Corporation; Virometix AG; U.S. Department of Defense; Geneva Foundation; Enesi Pharma; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Infectious Diseases Immunotherapies Vaccines Allergy Hepatitis B Department Of Defense Viruses HIV Immunodeficiency U.S. Department Of Defense Virus Malaria Fever Virology Ebola Zika Chronic Hepatitis Scripps Vaccinia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.5365 |
52 Week Low | 1.38 |
Average Volume | 30,842 |
200-Day Moving Average | 5.21 |
50-Day Moving Average | 1.77 |
20-Day Moving Average | 1.55 |
10-Day Moving Average | 1.62 |
Average True Range | 0.16 |
RSI (14) | 54.55 |
ADX | 14.76 |
+DI | 20.00 |
-DI | 15.03 |
Chandelier Exit (Long, 3 ATRs) | 1.31 |
Chandelier Exit (Short, 3 ATRs) | 1.87 |
Upper Bollinger Bands | 1.74 |
Lower Bollinger Band | 1.36 |
Percent B (%b) | 0.96 |
BandWidth | 24.25 |
MACD Line | -0.04 |
MACD Signal Line | -0.08 |
MACD Histogram | 0.046 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.96 | ||||
Resistance 3 (R3) | 1.96 | 1.88 | 1.92 | ||
Resistance 2 (R2) | 1.88 | 1.82 | 1.88 | 1.91 | |
Resistance 1 (R1) | 1.80 | 1.78 | 1.76 | 1.80 | 1.89 |
Pivot Point | 1.72 | 1.72 | 1.70 | 1.72 | 1.72 |
Support 1 (S1) | 1.64 | 1.66 | 1.60 | 1.64 | 1.55 |
Support 2 (S2) | 1.56 | 1.62 | 1.56 | 1.53 | |
Support 3 (S3) | 1.48 | 1.56 | 1.52 | ||
Support 4 (S4) | 1.48 |